{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T21:15:27Z","timestamp":1648934127152},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.arbres.2016.09.011","type":"journal-article","created":{"date-parts":[[2016,11,6]],"date-time":"2016-11-06T06:45:11Z","timestamp":1478414711000},"page":"212-213","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00bfEs la hiperplasia histioc\u00edtica nodular una causa del derrame pleural asociado con el dasatinib?"],"prefix":"10.1016","volume":"53","author":[{"given":"Satoshi","family":"Hamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Tsukino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2016.09.011_bib0055","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arbres.2016.09.011_bib0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MCP.0b013e328338c486","article-title":"Pleural effusions due to dasatinib","volume":"16","author":"Brixey","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.arbres.2016.09.011_bib0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haemotol"},{"key":"10.1016\/j.arbres.2016.09.011_bib0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","article-title":"Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect","volume":"89","author":"Paydas","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.arbres.2016.09.011_bib0075","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.leukres.2014.04.004","article-title":"Chronic myeloid leukemia patients who develop grade I\/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion","volume":"38","author":"Eskazan","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.arbres.2016.09.011_bib0080","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2016.09.011_bib0085","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-206841","article-title":"Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor","volume":"70","author":"Ustun","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2016.09.011_bib0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00000478-199803000-00002","article-title":"Lesions described as nodular mesothelial hyperplasia are primarily composed of histiocytes","volume":"22","author":"Ord\u00f3\u00f1ez","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.arbres.2016.09.011_bib0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anndiagpath.2004.03.001","article-title":"Nodular histiocytic\/mesothelial hyperplasia: A potential pitfall","volume":"8","author":"Chikkamuniyappa","year":"2004","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.arbres.2016.09.011_bib0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00000478-199706000-00005","article-title":"Nodular histiocytic\/mesothelial hyperplasia: A lesion potentially mistaken for a neoplasm in transbronchial biopsy","volume":"21","author":"Chan","year":"1997","journal-title":"Am J Surg Pathol"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289616302538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289616302538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T23:23:58Z","timestamp":1536276238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289616302538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0300289616302538"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2016.09.011","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfEs la hiperplasia histioc\u00edtica nodular una causa del derrame pleural asociado con el dasatinib?","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2016.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}